Core Viewpoint - The company announced a restricted stock incentive plan aimed at enhancing governance structure and motivating key employees to support long-term development and shareholder returns [1][2][3] Group 1: Incentive Plan Details - The incentive plan involves granting up to 6.23 million shares, representing 1.37% of the total share capital, with an initial grant of 4.99 million shares (80.06% of the total grant) [1] - The plan targets senior management, core technical personnel, middle management, and key employees to create a shared interest among shareholders, the company, and employees [1][3] Group 2: Performance Assessment Criteria - The performance assessment for the restricted stock includes metrics such as return on equity, revenue growth, R&D expenditure, and the number of approved drugs, with specific growth targets set for 2026-2028 [2] - Revenue growth targets are set at no less than 30%, 59%, and 80% for the respective years, with all growth rates required to exceed industry averages [2] Group 3: Product Development and Market Expansion - The company has developed a product matrix covering various therapeutic areas, including antifungal, psychiatric, diabetes, cancer, digestive, hypertension, kidney, and pain management [2] - Recent approvals from the FDA include the formal approval of tofacitinib citrate sustained-release tablets and temporary approval for other products, indicating a growing product pipeline [2] - In the domestic market, the company has received approvals for new specifications and has successfully participated in national drug procurement, enhancing its market presence [3]

Core Viewpoint - The company announced a restricted stock incentive plan aimed at enhancing corporate governance and aligning the interests of shareholders, the company, and employees, while also motivating and retaining key personnel [1][2]. Group 1: Incentive Plan Details - The incentive plan involves granting up to 6.23 million shares, representing approximately 1.37% of the company's total equity, with an initial grant of 4.99 million shares (80.06% of the total grant) [1]. - The plan targets senior management, core technical staff, middle management, and key personnel, aiming to establish a stable incentive mechanism [1]. Group 2: Performance Assessment Criteria - The plan includes performance assessment criteria based on multiple dimensions such as return on equity, revenue growth, R&D expenses, and the number of approved drugs, with specific growth targets set for 2026-2028 [2]. - The revenue growth targets are set at no less than 32%, 59%, and 80% for the respective years, with each year's growth rate required to exceed the industry average [2]. Group 3: Business Development and Product Pipeline - The company is actively investing in high-tech products and enhancing its research in injection formulations, with a product matrix covering various therapeutic areas including antifungal, psychiatric, diabetes, cancer, digestive, hypertension, kidney, and pain management [2]. - Recent international approvals include the formal approval of tofacitinib citrate extended-release tablets by the FDA and temporary approval for sitagliptin and metformin extended-release tablets, expanding the company's product offerings [2]. Group 4: Domestic Market Progress - In the domestic market, the company received approval for a new specification of sitagliptin and metformin extended-release tablets, enhancing its product portfolio in the diabetes sector [3]. - The successful selection of opaganib in the national drug centralized procurement and the inclusion of sitagliptin and metformin extended-release tablets in the national medical insurance directory are expected to boost market promotion and sales scale [3].